Pfizer EPS - Earnings per Share 2010-2024 | PFE

Pfizer annual and quarterly earnings per share history from 2010 to 2024. Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
  • Pfizer EPS for the quarter ending March 31, 2024 was $0.55, a 43.3% decline year-over-year.
  • Pfizer EPS for the twelve months ending March 31, 2024 was $-0.05, a 100.99% decline year-over-year.
  • Pfizer 2023 annual EPS was $0.37, a 93.24% decline from 2022.
  • Pfizer 2022 annual EPS was $5.47, a 42.08% increase from 2021.
  • Pfizer 2021 annual EPS was $3.85, a 136.2% increase from 2020.
Pfizer Annual EPS
2023 $0.37
2022 $5.47
2021 $3.85
2020 $1.63
2019 $2.82
2018 $1.87
2017 $3.52
2016 $1.17
2015 $1.11
2014 $1.42
2013 $3.19
2012 $1.94
2011 $1.27
2010 $1.02
2009 $1.23
Pfizer Quarterly EPS
2024-03-31 $0.55
2023-12-31 $-0.59
2023-09-30 $-0.42
2023-06-30 $0.41
2023-03-31 $0.97
2022-12-31 $0.86
2022-09-30 $1.51
2022-06-30 $1.73
2022-03-31 $1.37
2021-12-31 $0.59
2021-09-30 $1.42
2021-06-30 $0.98
2021-03-31 $0.86
2020-12-31 $0.15
2020-09-30 $0.26
2020-06-30 $0.62
2020-03-31 $0.60
2019-12-31 $-0.11
2019-09-30 $1.36
2019-06-30 $0.89
2019-03-31 $0.68
2018-12-31 $-0.06
2018-09-30 $0.69
2018-06-30 $0.65
2018-03-31 $0.59
2017-12-31 $2.03
2017-09-30 $0.47
2017-06-30 $0.51
2017-03-31 $0.51
2016-12-31 $0.13
2016-09-30 $0.22
2016-06-30 $0.33
2016-03-31 $0.49
2015-12-31 $-0.03
2015-09-30 $0.34
2015-06-30 $0.42
2015-03-31 $0.38
2014-12-31 $0.19
2014-09-30 $0.42
2014-06-30 $0.45
2014-03-31 $0.36
2013-12-31 $0.44
2013-09-30 $0.39
2013-06-30 $1.98
2013-03-31 $0.38
2012-12-31 $0.84
2012-09-30 $0.43
2012-06-30 $0.43
2012-03-31 $0.24
2011-12-31 $0.18
2011-09-30 $0.48
2011-06-30 $0.33
2011-03-31 $0.28
2010-12-31 $0.35
2010-09-30 $0.11
2010-06-30 $0.31
2010-03-31 $0.25
2009-12-31 $0.06
2009-09-30 $0.43
2009-06-30 $0.34
2009-03-31 $0.40
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $162.291B $58.496B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $731.812B 105.77
Novo Nordisk (NVO) Denmark $591.861B 45.48
Johnson & Johnson (JNJ) United States $372.169B 14.78
Merck (MRK) United States $332.279B 60.46
AbbVie (ABBV) United States $293.876B 15.18
AstraZeneca (AZN) United Kingdom $238.424B 20.73
Novartis AG (NVS) Switzerland $209.653B 14.86
Sanofi (SNY) $123.116B 11.62
Innoviva (INVA) United States $0.998B 7.01